Citations 1
Considerations for the Use of Phage Therapy in Clinical Practice
Suh, Gina A. , Lodise, Thomas P. , Tamma, Pranita D. , Knisely, Jane M., Alexander, Jose, Aslam, Saima, Barton, Karen D., Bizzell, Erica, Totten, Katherine M. C. , Campbell, Joseph L., Chan, Benjamin K., Cunningham, Scott A., Goodman, Katherine E., Greenwood-Quaintance, Kerryl E., Harris, Anthony D., Hesse, Shayla , Maresso, Anthony, Nussenblatt, Veronique, Pride, David , Rybak, Michael J. , Sund, Zoe, Tyne, Daria Van , Patel, Robin , Group, for the Antibacterial Resistance Leadership, Barton, Karen D. , van Duin, David , Van Tyne, Daria , Patel, Robin , Tamma, Pranita D , Suh, Gina A , Lodise, Thomas P. , Knisely, Jane M., Alexander, Jose, Aslam, Saima, Bizzell, Erica, Totten, Katherine M. C. , Campbell, Joseph L., Chan, Benjamin K., Cunningham, Scott A., Goodman, Katherine E., Greenwood-Quaintance, Kerryl E., Harris, Anthony D., Hesse, Shayla , Maresso, Anthony, Nussenblatt, Veronique, Pride, David , Rybak, Michael J , Sund, Zoe, Group, for the Antibacterial Resistance Leadership
Antimicrobial Agents and Chemotherapy | January 18, 2022 | Volume: 66 | Issue: 3 | Pages: No page available
Increasing antimicrobial resistance and medical device-related infections have led to a renewed interest in phage therapy as an alternative or adjunct to conventional antimicrobials. Expanded access and compassionate use cases have risen exponentially but have varied widely in approach, methodology, clinical situations in which phage therapy might be considered, dosing, route of administration, and outcomes.